Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 919-935

  Raja Khan, Nazia ^a   Warehime, Sarah S ^a   Gabbay, Robert A ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Biphasic insulin aspart; Diabetes; Insulin

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPHASIC INSULIN; CLONIDINE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ADJUVANT THERAPY; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; BODY MASS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG CHOICE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; EVENING DOSAGE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; MORNING DOSAGE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 38149000115     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. American Diabetes Association. 2007. Standards of medical care in diabetes-2007. Diabetes Care, 30:S4-41.
2. Abrahamian H, Ludvik B, Schernthaner G, et al. 2005. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs modern insulin regimens (results from the Austrian Biaspart Study). Horm Metab Rex, 37:684-9.
3. Blonde L. 2005. Current challenges in diabetes management. Clin Cornerstone, 7(Suppl 3):S6-17.
4. Boehm BO, Home PD, Behrend C, et al. 2002. Premixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: A randomized trial in type 1 and type 2 diabetic patients. Diabet Med, 19:393-9.
5. Boehm BO, Vaz JA, Brondsted L, et al. 2004. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med, 15:496-502.
6. CDC: National Diabetes Fact Sheet. 2005. Accessed 10 April 2007. URL: http://www.cdc.gov/diabetes/pubs/factsheet05.htm
7. Chen JW, Frystyk J, Lauritzen T, et al. 2005. Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes. Eur J Endocrinol, 153:907-13.
8. Chen JW, Lauritzen T, Bojesen A, et al. 2006. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes. Diabetes Obes Metab, 8:682-9.
9. Christiansen JS, Vaz JA, Metelko Z, et al. 2003. Twice daily biphasic insulin aspart improves postprandial glycemic control more effectively than twice daily NPH insulin, with low risk of hypoglycemia, in patients with type 2 diabetes. Diabetes Obes Metab, 5:446-54.
10. Daneman D. 2006. Type 1 diabetes. Lancet, 367:847-58.
11. Davidson J, Vexiau P, Cucinotta D, Vaz J, et al. 2005. Biphasic insulin aspart 30: literature review of adverse events associated with treatment. Clin Ther, 27(Suppl 2):S75-88.
12. DCCT (Diabetes Control and Complications Trial)/Epidemiology of Diabetes Interventions and Complications Research Group. 2000. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med, 342:381-9.
13. DECODE Study Group, European Diabetes Epidemiology Group. 2003. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care, 26:688-96.
14. Garber AJ. 2006. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs, 66:31-49.
15. Garber AJ, Wahlen J, Wahl T, et al. 2006. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab, 8:58-66.
16. Halimi S, Raskin P, Liebl A, et al. 2005. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther, 27:S57-74.
17. Henderson JN, Allen KV, Deary IJ, et al. 2003. Hypoglycemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med, 20:1016-21.
18. Hermansen K, Colombo M, Storgarrd H, et al. 2002. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care, 25:883-8.
19. Hermansen K, Vaaler S, Madsbad S, et al. 2002. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. Metabolism, 51:896-900.
20. Home PD, Barriocanal L, Lindholm A. 1999. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol, 55:199-203.
21. International Diabetes Federation. 2007. Diabetes Atlas. 3rd ed. Accessed 10 April 2007. URL: http://www.eatlas.idf.org/media/.
22. IDF Clinical Guidelines Task Force. 2006. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med, 23:579-93.
23. Iwamoto Y. 2003. A randomized, multcentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes. Diabetologia, 46(Suppl 2):A270.
24. Jacobsen LV, Sogaard B, Riis A. 2000. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol, 56:399-403.
25. Jain R, Wahl T, Wahlen J, et al. 2004. Patients with type 2 diabetes can achieve A1c targets with once-daily biphasic insulin aspart 70/30 (NovoLog Mix 70/30) before supper. Diabetes, 53(Suppl2):A130.
26. Johnson JA, Pohar SL, Majumdar SR. 2006. Health care use and costs in the decade after identification of type 1 and type 2 diabetes: a population-based study. Diabetes Care, 29:2403-8.
27. Kann PH, Wascher T, Zackova V, et al. 2006. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepride. Exp Clin Endocrinol Diabetes, 114:527-32.
28. Kapitza C, Rave K, Ostrowski K, et al. 2004. Reduced postprandial glycaemic excursion with biphasic; insulin aspart 30 injected immediately before a meal. Diabet Med, 21:500-1.
29. Kilo C, Mezitis N, Jain R, et al. 2003. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications, 17:307-13.
30. Koro CE, Bowlin SJ, Bourgeois N, et al. 2004. Glycemic control from 1988-2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care, 27:17-20.
31. Korytkowski M, Nskanen L, Asakura T. 2005. FlexPen®: Addressing issues of confidence and convenience in insulin delivery. Clin Ther, 27:S89-100.
32. Kvapil M, Swatko A, Hilberg C, et al. 2006. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab, 8:39-48.
33. Landgraf R. 2004. The relationship of postprandial glucose to HbA1c. Diabetes Metab Res Rec, 20(Suppl 2):S9-12.
34. Lebovitz HE, Austin MM, Blonde L, et al. 2006. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract, 12(Suppl1):6-12.
35. Leiter LA, Ceriello A, Davidson JA, et al. 2005. International Prandial Glucose Regulation (PGR) Study Group. Postprandial glucose regulation: New data and new implications. Clin Ther, 27:S42-56.
36. Ligthelm RJ, Mouritzen U, Lynggaard H, et al. 2006. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomized open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes, 114:511-9.
37. Lindholm A, Jensen LB, Home PD, et al. 2002. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care, 25:876-82.
38. McSorley PT, Bell PM, Jacobsen LV, et al. 2002. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther, 24:530-9.
39. Monnier L, Lapinski H, Colette C. 2003. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetes: Variations with increasing levels of HbA1c. Diabetes Care, 26:881-5.
40. Mortensen H, Kocova M, Teng LY, et al. 2006. Biphasic insulin aspart vs human insulin in adolescents with type 1 diabetes on multiple daily insulin injections. Pediatr Diabetes, 7:1-3.
41. Mudaliar S, Edelman SV. 2001. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am, 30:935-82.
42. Nathan DM, Cleary PA, Backlund JY (DCCT). 2005. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 353:2643-53.
43. Nauck MA, Duran S, Kim D, et al. 2007. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia, 50:259-67.
44. Niskanen L, Jensen LE, Rastam J, et al. 2004. Randomized, multinational open-label, 2-period crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther, 26:531-40.
45. Nolan JJ, O'Halloran D, McKenna TJ, et al. 2006. The cost of treating type 2 diabetes (CODEIRE). Ir Med J, 100:307-10.
46. Provider Synergies LLC. 2006. Hypoglycemics. Insulins Review.
47. Raskin PR, Allen E, Hollander P, et al. 2005. Initiating insulin therapy in type 2 diabetes. Diabetes Care, 28:260-5.
48. Raskin PR, Hollander PA, Lewin A, et al. 2007. on behalf of the INITIATE Study Group. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med, 18:56-62.
49. Ray JA, Valentine WJ, Roze S, et al. 2007. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs insulin glargine in the US. Diabetes Obes Metab, 9:103-13.
50. Raz I, Stranks S, Filipczak R, et al. 2005. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clin Ther, 27:1432-43.
51. RiddLe MC, Rosenstock J, Gerich J. 2003. for the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 26:3080-6.
52. Rolla AR, Rakel RE. 2005. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther, 27:1113-25.
53. Schmoelzer I, de Campo A, Pressl H, et al. 2005. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes, 113:176-81.
54. Sicat BL, Morgan LA. 2007. New therapeutic options for the management of diabetes. Consult Pharm, 22:45-56.
55. Stumvoll M, Goldstein BJ, van Haeften TW. 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 365:1333-46.
56. Temelkova-Kurktschiev TS, Koehler C, Henkel E, et al. 2000. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care, 23:1830-4.
57. Tibaldi J, Rakel RE. 2007. Why, when and how to initiate insulin therapy in patients with type 2 diabetes. Int J Clin Pract, 61:633-44.
58. Valentine WJ, Palmer AJ, Lammert M, et al. 2005. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients; cost-effectiveness analysis in the UK setting. Curr Med Res Opin, 21:2063-71.
59. UK Prospective Diabetes Study (UKPDS) Group. 1998. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352:837-53.
60. Wild S, Roglic G, Green A, et al. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27:1047-53.